Syreon Research Institute’s Post

📣 New article published! The recently published paper authored by Syreon Research Instituteteam, entitled: 'Tradeoffs When Building and Running Cohort and Patient-Level Markov Simulation Models'. Congratulations to all co-authors! Link to the paper: https://lnkd.in/dJ7Fr_3q #HaDEA, #EU, #healthtechnologyassessment, #multiplesclerosis, #healthcaremodelingapproaches, #Markovmodeling

Discover QuantiNova's Research Tools Power! 🌟 Discover how QuantiNova's tools can speed up your medical research. With easy-to-use analytics, dive deep into your data and get clear, fast results. Whether you're a beginner or an expert, QuantiNova makes your research journey smoother and more efficient. Start exploring today and see the difference! 🚀🔬 . . #ResearchMadeEasy #MedicalBreakthroughs #QuantiNova #MedicalResearchJourney #wlnc #wlnc2024 #icurestroke #neuroinnovation #neurointervention #medicalconference #neurologyupdate #medicaladvancements #cerebrovascularhealth #patientcare #espghan2024 #ESPGHAN #Probiotical #doctorsconference #pediatricassociates #Googlescholar #Research #Researchskills #trending #trendingreels #reels #viral #viralreeĺs

GE HealthCare recently received 𝗙𝗗𝗔 𝗰𝗹𝗲𝗮𝗿𝗮𝗻𝗰𝗲 for its new Centiloid scaling tool, integrated into the MIMneuro software, to enhance Alzheimer’s disease imaging. This tool quantifies amyloid plaque density in the brain using PET scans, providing a standardized and automated metric that 𝗮𝗶𝗱𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗶𝗮𝗻𝘀 𝗶𝗻 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝗻𝗴 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 with greater confidence. 𝗔𝗺𝘆𝗹𝗼𝗶𝗱 𝗽𝗹𝗮𝗾𝘂𝗲𝘀 are a 𝗸𝗲𝘆 𝗺𝗮𝗿𝗸𝗲𝗿 𝗼𝗳 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 disease, and the Centiloid scale standardizes their measurement, making results comparable across various imaging centers. This development is particularly timely as new amyloid-targeting therapies enter the market, further increasing the need for precise diagnostic tools. With this technology, clinicians can now better determine which patients may benefit from these treatments. At Medidedalia, we recognize the importance of advancing diagnostic accuracy in neurodegenerative diseases. Tools like GE HealthCare’s MIMneuro software align with our mission to enhance personalized care, ultimately improving patient outcomes through early detection and tailored treatments. You can read the full article here: https://lnkd.in/dTJXyZCs #HealthcareInnovation #AIinHealthcare #MedTech #AlzheimersCare #BrainHealth #ImagingTechnology #AI #FDAApproval #NeurodegenerativeDiseases #PETImaging #AmyloidPlaque #DigitalHealth #PrecisionMedicine #PatientCare #MedicalAI #HealthcareTech #MolecularImaging #AIforGood #HealthcareTransformation

We're pleased to introduce our novel Causal Responders Detection (CARD) method, detailed in our latest publication. CARD applies machine learning and causal tree techniques to identify individuals who benefit significantly from treatments, ensuring false discovery control in both RCTs and observational studies. This method refines our understanding of individual treatment responses, providing crucial insights for precision medicine development. Our simulations confirm CARD's effectiveness across various settings, enabling to apply this method across therapeutic areas and clinical phases. #PersonalizedMedicine #MachineLearning #ClinicalTrials #HealthcareInnovation Tzviel Frostig Oshri Machluf Elad Berkman Raviv Pryluk Amitay Kamber

🔍 𝐑𝐞𝐭𝐢𝐧𝐚𝐥 𝐓𝐡𝐢𝐜𝐤𝐧𝐞𝐬𝐬 𝐚𝐧𝐝 𝐌𝐚𝐜𝐡𝐢𝐧𝐞 𝐋𝐞𝐚𝐫𝐧𝐢𝐧𝐠: 𝐄𝐧𝐡𝐚𝐧𝐜𝐢𝐧𝐠 𝐆𝐥𝐚𝐮𝐜𝐨𝐦𝐚 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬 𝐚𝐧𝐝 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐏𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐨𝐧 Recent research highlights how retinal thickness measurements, including the retinal nerve fiber layer (RNFL) and ganglion cell inner plexiform layer (GC-IPL), are key to predicting glaucoma progression. For early-stage glaucoma, RNFL is most effective in predicting visual field worsening, while GC-IPL is more suitable for moderate to advanced disease stages. Machine learning models have shown superior accuracy compared to traditional statistical approaches, enhancing the diagnostic process and providing valuable insights into disease progression. The study also revealed that combining RNFL and GC-IPL measurements did not significantly improve predictive performance, as each layer is effective for different disease stages. This research emphasizes the growing role of advanced retinal imaging and machine learning in glaucoma management, helping clinicians make more accurate, personalized treatment decisions for better patient outcomes. 💬 𝗜𝘀 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗿𝗲𝘁𝗶𝗻𝗮𝗹 𝗶𝗺𝗮𝗴𝗶𝗻𝗴 𝗼𝗿 𝗺𝗮𝗰𝗵𝗶𝗻𝗲 𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗶𝗻 𝘆𝗼𝘂𝗿 𝗰𝗹𝗶𝗻𝗶𝗰? 𝗛𝗼𝘄 𝗮𝗿𝗲 𝘆𝗼𝘂 𝘂𝘀𝗶𝗻𝗴 𝗶𝘁 𝘁𝗼 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗴𝗹𝗮𝘂𝗰𝗼𝗺𝗮 𝗰𝗮𝗿𝗲 𝗮𝗻𝗱 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀? 𝗦𝗵𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝘁𝗵𝗼𝘂𝗴𝗵𝘁𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀. #Verovian #Healthcare #Recruitment #Optometry #GlaucomaCare #RetinalImaging #MachineLearning #EyeHealth #VisionScience #OpticalInnovation #USNews #Glaucoma #USHealthcare #HealthNews #OptometryJobs #JoinUs #VorovianRecruitment #USJobs #NowHiring

Research in itself is essential. When we can translate some of the research into clinical research, then it gets one step closer to the patient, future treatments and better quality of life for many people. When the disgnostic tools then translate into clinical use, it’s a huge and rare step. There are so many instances of DTI being an amazing research tool, lots of them are translating into clinical trials. And now, we have a direct way to the clinic with ANDI, it’s time to make DTI actionable for patients today. #DTI #Brain #TBI #imaging

🚀 Dive into the Future of Clinical Trials with Dr. Daniel Gehrlach, Associate Director for Biomarkers from HMNC Brain Health! 🌟 🧠 HMNC Brain Health is a Munich startup that is about to pioneer the area of precision medicine, specifically #PrecisionPsychiatry. 💡 Daniel sheds light on the complexities and innovations in clinical trials. From genetic selection tools to the challenges of regulatory compliance, he discusses how new technologies like decentralized trials and AI can revolutionize the field. To help you navigate to the sections that interest you the most, use this guidance: 📌 0:15 Introduction 📌 1:36 Regulation of Clinical Trials 📌 4:04 Speech Analysis 📌 5:17 Decentralized Trials 📌 7:39 Time to Market 📌 8:34 Why "being brave" matters 📌 9:10 The right CRO 🧬 For more on technology trends and how they can enhance efficiency in clinical trials, check out the full video or look at some of my other interviews. 🌍 Let's explore how we can push the boundaries of life sciences together! #LifeSciences #ClinicalTrials #PrecisionMedicine #Innovation #Technology #DecentralizedTrials

Recent research from the University of Cambridge highlights the powerful potential of diffusion tensor #imaging (DTI) in predicting outcomes for #concussion patients. Using DTI, we can detect abnormalities in water flow within the axons of white matter—revealing possible damage caused by traumatic #brain injury (TBI) or concussions. What’s particularly groundbreaking is how #DTI can identify the one in three concussion patients at risk of ongoing issues like severe #fatigue, #memoryloss, and #mentalhealth challenges. These symptoms can profoundly affect daily life, making early detection and follow-up care essential. Reach out to our imaging experts to discuss how to bring DTI into your #clinicaltrials: mailto:imaging.experts@ia-grp.com or visit: https://www.ia-grp.com Source: https://lnkd.in/eGzh9jTY Image Analysis Group is a leading imaging Clinical Research Organization. DYNAMIKA™: The AI-powered platform revolutionizing clinical trial imaging. Precision. Speed. Reliability. Learn how we're reshaping medical research at https://www.ia-grp.com #MedTech #AIinHealthcare

How will it all work in the near-term future as we integrate screening+treating folks for memory loss and use of digital technologies? Will it be critical for Alzheimer's and Parkinson's? You bet it will. Enter the Digitized Memory Clinic by Gramkow and colleagues as laid out in their new paper in Nature Reviews Neurology. Key Points: - The authors suggest a simple tiered approach. - Tiers 1-3 are diagnostic and monitoring and include critical person-centered assessments. - Tier 4 is post-diagnostic care. My take: I love that the construct does not make the physician the sun. The person w/ memory loss is the sun, and all healthcare team members, not just the doc, orbit around them, and of course use the digital technology. I love that this will bring care to more people and do it in their homes. The AI-driven software is squishy today, but I can see this developing quickly, and of course will feed much better clinical decision support tools. This will facilitate the critical need for disease tracking, All of this will be much better once we break through with more effective treatments for memory dysfunction. This idea will drive clinical trials faster and this will be a very good thing. We have not arrived at a digital memory clinic, however I think we can all close our eyes and imagine the near-term future. https://lnkd.in/ei2M2qqu

An important missing link in treatment efficacy research. https://lnkd.in/gsRkJda5 I wrote about this idea way back in 2019: https://lnkd.in/gUnBgsNn